The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Inclusion Criteria:

Phase 1b:

* Patients 18 years or older at time of consent
* Mild-to-Moderate AD, defined as:
* BSA ≤ 10%
* IGA ≤ 3
* No past biologic therapy
* No systemic therapy for 3 months
* No topical therapy for treatment of AD for 4 weeks

Phase 2:

* Patients 18 years or older at time of consent
* Mild-to-Moderate AD, defined as:
* BSA ≤ 10%
* IGA ≤ 3
* At least one patch of eczema of at least 5 cm in diameter
* No past biologic therapy
* No systemic therapy for 3 months
* No topical therapy for treatment of AD for 4 weeks

Exclusion Criteria:

Phase 1b:

* Age less than 18 years old
* Pregnant or breastfeeding
* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
* Has used topical therapy for treatment of AD within 4 weeks

Phase 2:

* Patients enrolled in Phase 1
* Age less than 18 years old
* Pregnant or breastfeeding
* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
* Has used topical therapy for treatment of AD within 4 weeks